Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Return on Sales (2016 - 2025)

Immucell's Return on Sales history spans 16 years, with the latest figure at 0.37% for Q4 2025.

  • For Q4 2025, Return on Sales fell 44.0% year-over-year to 0.37%; the TTM value through Dec 2025 reached 0.04%, up 4.0%, while the annual FY2025 figure was 0.04%, 4.0% up from the prior year.
  • Return on Sales reached 0.37% in Q4 2025 per ICCC's latest filing, down from 0.03% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.18% in Q1 2025 to a low of 0.67% in Q1 2023.
  • Average Return on Sales over 5 years is 0.15%, with a median of 0.11% recorded in 2021.
  • Peak YoY movement for Return on Sales: plummeted -76bps in 2023, then skyrocketed 61bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.01% in 2021, then tumbled by -3232bps to 0.43% in 2022, then decreased by -9bps to 0.47% in 2023, then surged by 114bps to 0.07% in 2024, then crashed by -663bps to 0.37% in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Return on Sales are 0.37% (Q4 2025), 0.03% (Q3 2025), and 0.08% (Q2 2025).